
EC Approves Pfizer’s Biosimilar to Roche’s Herceptin
The European Commission (EC) approved Pfizer’s Trazimera (trastuzumab), a biosimilar to Roche’s Herceptin, to treat certain breast and gastric cancers.
On July 31, 2018, the European Commission (EC) approved Pfizer’s Trazimera (trastuzumab), a biosimilar to Roche’s Herceptin, for treating human epidermal growth factor (HER2)-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma cancer. Herceptin, a top-selling product for Roche, made CHF 7.01 billion (US$7.04 billion) in
Pfizer states that Trazimerais the company’s fourth biosimilar to receive European approval. Pfizer’s biosimilars pipeline consists of nine distinct Pfizer and legacy Hospira biosimilar molecules in various stages of development. Pfizer acquired Hospira in
Pfizer’s trastuzumab to date is not approved by FDA. In
In
“The approval of Trazimera, Pfizer’s first oncology biosimilar, is another significant step in our quest to introduce more treatment options for patients in Europe,” said Richard Blackburn, global president, Pfizer Essential Health Europe, Africa/Middle East and Biosimilars, in a company press release. “Pfizer is investing in developing and launching a range of biosimilars which can help to reduce healthcare costs and increase patient access to important medicines.”
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.